Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

S&P Pharmaceuticals SPDR (XPH)

S&P Pharmaceuticals SPDR (XPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family State Street Global Advisors
  • Assets Under Management 252,482,100
  • Market Capitalization, $K 252,482
  • Shares Outstanding, K 5,250
  • 60-Month Beta 1.15
Trade XPH with:
  • Price/Earnings ttm 11.22
  • Annual Dividend & Yield 0.26 (0.55%)
  • Most Recent Dividend 0.052 on 09/21/20
  • Management Fee 0.35%
  • Sectors:

    ETFs - Biotech

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.61 +9.81%
on 10/29/20
49.17 -2.60%
on 11/18/20
+1.50 (+3.23%)
since 10/23/20
3-Month
42.14 +13.64%
on 09/04/20
49.17 -2.60%
on 11/18/20
+4.06 (+9.26%)
since 08/25/20
52-Week
30.30 +58.05%
on 03/18/20
49.17 -2.60%
on 11/18/20
+7.41 (+18.31%)
since 11/25/19

Most Recent Stories

More News
ETFs to Shine on Lilly's Coronavirus Antibody Progress

Eli Lilly's (LLY) progress in antibodies treatment is expected to raise investors' optimism.

PPH : 64.81 (-0.08%)
PJP : 66.81 (-0.61%)
IHE : 170.53 (-0.26%)
XPH : 47.89 (-0.42%)
3 Reasons to Bet on Healthcare ETFs

The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.

AZN : 52.60 (-1.81%)
PFE : 36.53 (-0.19%)
GILD : 59.50 (-1.24%)
MRNA : 109.18 (+10.78%)
LLY : 144.75 (-0.10%)
PPH : 64.81 (-0.08%)
PJP : 66.81 (-0.61%)
XPH : 47.89 (-0.42%)
PSCH : 154.94 (-0.15%)
XHS : 89.56 (-0.63%)
FTXH : 24.84 (-0.91%)
Should You Invest in the SPDR SP Pharmaceuticals ETF (XPH)?

Sector ETF report for XPH

XPH : 47.89 (-0.42%)
RPRX : 40.97 (+3.51%)
HZNP : 68.90 (-0.20%)
PJP : 66.81 (-0.61%)
IHE : 170.53 (-0.26%)
MYOK : 224.91 (+0.05%)
Q3 Earnings Fail to Impress Pharma ETFs

The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.

PPH : 64.81 (-0.08%)
PJP : 66.81 (-0.61%)
IHE : 170.53 (-0.26%)
XPH : 47.89 (-0.42%)
FTXH : 24.84 (-0.91%)
ETFs to Shine on Lilly's U.S. Deal for Coronavirus Antibody

Eli Lilly's (LLY) progress in antibodies treatment is expected to raise investors' optimism.

PPH : 64.81 (-0.08%)
PJP : 66.81 (-0.61%)
IHE : 170.53 (-0.26%)
XPH : 47.89 (-0.42%)
Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal

These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.

BMY : 62.84 (-0.60%)
XBI : 126.82 (+0.60%)
XPH : 47.89 (-0.42%)
BBC : 44.61 (+0.97%)
SBIO : 47.28 (+0.77%)
MYOK : 224.91 (+0.05%)
ARKG : 74.73 (+0.01%)
Pharma ETFs to Benefit from Lilly's Coronavirus Antibody Progress

Lilly's progress in antibodies treatment is expected to raise investors optimism.

PPH : 64.81 (-0.08%)
PJP : 66.81 (-0.61%)
IHE : 170.53 (-0.26%)
XPH : 47.89 (-0.42%)
Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

JNJ : 143.68 (-0.13%)
PFE : 36.53 (-0.19%)
MRK : 80.06 (-0.10%)
LLY : 144.75 (-0.10%)
BMY : 62.84 (-0.60%)
PPH : 64.81 (-0.08%)
PJP : 66.81 (-0.61%)
IHE : 170.53 (-0.26%)
XPH : 47.89 (-0.42%)
FTXH : 24.84 (-0.91%)
TOP 4 COVID Stocks to Buy Before a Vaccine is Created

As coronavirus cases continue to soar, the U.S. is in desperate need of a vaccine. Who will get there first? Here are four candidates to consider: AstraZeneca (AZN), Novavax (NVAX), Pfizer (PFE), and Moderna...

AZN : 52.60 (-1.81%)
NVAX : 102.60 (+7.63%)
PFE : 36.53 (-0.19%)
MRNA : 109.18 (+10.78%)
XPH : 47.89 (-0.42%)
VRTX : 218.10 (+0.74%)
5 Sector ETFs Just Got Upgraded to Buy

Zacks recently issued quarterly rank updates for ETFs and these sector ETFs have been upgraded to Buy.

RTH : 157.88 (+0.06%)
KBE : 40.47 (-1.46%)
PJP : 66.81 (-0.61%)
IYZ : 29.85 (-0.43%)
XPH : 47.89 (-0.42%)
VOX : 115.33 (-0.05%)
VFH : 70.45 (-0.48%)
IYJ : 191.91 (-0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The SPDR SP Pharmaceuticals ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the SP Pharmaceuticals Select Industry Index.

See More

Key Turning Points

2nd Resistance Point 48.16
1st Resistance Point 48.03
Last Price 47.89
1st Support Level 47.63
2nd Support Level 47.36

See More

52-Week High 49.17
Last Price 47.89
Fibonacci 61.8% 41.96
Fibonacci 50% 39.74
Fibonacci 38.2% 37.51
52-Week Low 30.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar